Second quarter 2022 results
Second quarter 2022 results were reviewed by management during a conference call with the financial community. The presentation was followed by a Q&A session.
Featuring
![Paul Hudson](/optim/dotcom/content-app/events/quaterly-results/2022/q4-results-2022/PHudson_20230417070709.jpg?size=small)
Paul Hudson
Chief Executive Officer
![Jean-Baptiste de Chatillon](/optim/dotcom/content-app/events/quaterly-results/2022/q4-results-2022/JBdeChatillon_20230417070431.png?size=small)
Jean-Baptiste de Chatillon
Chief Financial Officer
![Bill Sibold](/optim/dotcom/content-app/events/quaterly-results/2022/q4-results-2022/BillSibold_20230417070309.png?size=small)
Bill Sibold
Specialty Care
![Olivier Charmeil](/optim/dotcom/content-app/events/quaterly-results/2022/q4-results-2022/OlivierCharmeil_20230417070553.png?size=small)
Olivier Charmeil
General Medicines
![John Reed](/optim/dotcom/content-app/events/quaterly-results/2022/q4-results-2022/J-Reed_20230417070457.jpg?size=small)
John Reed
R&D
![Thomas Triomphe](/optim/dotcom/content-app/events/quaterly-results/2022/q4-results-2022/ThomasTriomphe_20230417070802.png?size=small)
Thomas Triomphe
Vaccines
![Julie Van Ongevalle](/optim/dotcom/content-app/events/quaterly-results/2022/q4-results-2022/JVOngevalle_20230417070525.png?size=small)
Julie Van Ongevalle
Consumer Healthcare
![Roy Papatheodorou](/optim/dotcom/content-app/events/quaterly-results/2022/q4-results-2022/Papathedorou-circle_20230417070637.png?size=small)
Roy Papatheodorou
General Counsel
Highlights
Our performance in the second quarter was once again fueled by both higher sales across our key growth drivers and outstanding financial results. We remain ahead of schedule on our strategy and are confident in the outlook for the second half of the year.
![Paul Hudson](/optim/dotcom/content-app/events/quaterly-results/2022/q4-results-2022/ph.jpeg?size=small)
Paul Hudson
Chief Executive Officer, Sanofi